Prescient Therapeutics Ltd has released a press release.
PTX-200 Breast Cancer Trial Progresses
Filed with ASX ·
6ix hasn’t read this filing yet.
Prescient Therapeutics Limited on 6ix
Earlier from Prescient Therapeutics
- Steven Yatomi-Clarke Appointed CEO
- December 2015 Appendix 4C - Quarterly
- Virax secures $3 million placement
- Virax close out of VIR201 HIV Vaccine Phase IIa Trial
- VIR201 HIV Vaccine Phase IIa Trial Results - 16 August 2010
Later from Prescient Therapeutics
- Approval received to transfer IND Sponsorship for PTX-200
- December 2014 Appendix 4C - quarterly
- Encouraging Pre-Clinical Data Presented at US Cancer Meeting
- IND for Phase 1b/2 Ovarian Cancer Trial Transferred to PTX
- June 2015 Appendix 4C - Quarterly
Follow Prescient Therapeutics into a list and get an email when it puts out news.
Follow Prescient Therapeutics